A Phase 3, Randomized, Double-blind, Multi-country Study to Evaluate Consistency, Safety, and Reactogenicity of 3 Lots of RSVPreF3 OA Investigational Vaccine Administrated as a Single Dose in Adults Aged 60 Years and Above
Latest Information Update: 18 Feb 2023
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary) ; AS01E
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics; Registrational
- Acronyms RSV OAADJ-009
- Sponsors GlaxoSmithKline; GSK
- 05 Aug 2022 Status changed from active, no longer recruiting to completed.
- 27 Jun 2022 Planned End Date changed from 24 Jun 2022 to 11 Jul 2022.
- 08 Feb 2022 Planned End Date changed from 4 Jul 2022 to 24 Jun 2022.